Would you continue venetoclax indefinitely/until disease progression in patients treated with upfront venetoclax for TP53 mutated CLL?
Answer from: Medical Oncologist at Academic Institution
First of all, for the del(17)(p13.1) and/or TP53 mutated CLL patients, venetoclax + obintuzumab may not be the best option based upon data from the CLL14 trial showing early PFS in this group as compared to what has been demonstrated in both up-front ibrutinib and acalabrutinib studies. However, we ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I think this is a complicated question for which we need more long-term data. There are many of us who prefer continuous BTKis in this high-risk patient population (until we have long-term data on BTKi-Ven combination). If they cannot take BTKis, venetoclax-based therapy is recommended for these pat...